Indications › Type 2 diabetes › dulaglutide

dulaglutide in type 2 diabetes

dulaglutide is approved in the US for type 2 diabetes, and has 49 trials on file here in this condition. 35 of them are phase 3 or later. The next scheduled result is 2027-03-30.

49 registered trials study dulaglutide (Trulicity) in type 2 diabetes, 7 of them still active and 4 in phase 3. The next is due to report 2027-03-30.

Trials on file: 49
Active: 7
Active phase 3: 4
Participants in active trials: 2,115
Sponsors: 17
Scheduled readouts: 2

Scheduled to report

Dates are filed by the sponsor and move often. Each links to its own record and change history.

Est. completion	Trial	Phase	Participants
2027-03-30	A Phase 3 Study of HS-20094 in Patients With T2DM NCT07156539 · Jiangsu Hansoh Pharmaceutical Co., Ltd.	P3	546
2027-04	Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease NCT07537088 · First Affiliated Hospital of Wannan Medical College	P4	468

All trials on file

Every registered trial of dulaglutide grouped under type 2 diabetes, largest first. Grouping follows the registry’s own condition wording.

Trial	Status	Phase	Sponsor
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) NCT01394952	Completed	P3	Eli Lilly and Company
A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes NCT03495102	Completed	P3	Eli Lilly and Company
A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin NCT00734474	Completed	P2/P3	Eli Lilly and Company
A Study in Participants With Type 2 Diabetes Mellitus NCT01064687	Completed	P3	Eli Lilly and Company
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin NCT03684642	Terminated	P3	Sanofi
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4) NCT01191268	Completed	P3	Eli Lilly and Company
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2) NCT01075282	Completed	P3	Eli Lilly and Company
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3) NCT01126580	Completed	P3	Eli Lilly and Company
A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus NCT01648582	Completed	P3	Eli Lilly and Company
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes NCT01149421	Completed	P2	Eli Lilly and Company
A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus NCT01644500	Completed	P3	Eli Lilly and Company
A Study of IBI362 in Participants With Type 2 Diabetes NCT05606913	Completed	P3	Innovent Biologics (Suzhou) Co. Ltd.
A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus NCT06235086	Completed	P3	CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM NCT05680129	Completed	P3	Hangzhou Sciwind Biosciences Co., Ltd.
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin NCT06257966	Active, not recruiting	P3	Beijing Dongfang Biotech Co., Ltd.
A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes NCT04809220	Completed	P3	Eli Lilly and Company
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) NCT01621178	Completed	P3	Eli Lilly and Company
A Phase 3 Study of HS-20094 in Patients With T2DM NCT07156539	Not yet recruiting	P3	Jiangsu Hansoh Pharmaceutical Co., Ltd.
Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease NCT07537088	Not yet recruiting	P4	First Affiliated Hospital of Wannan Medical College
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus NCT02597049	Completed	P3	Eli Lilly and Company
A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus NCT01468181	Completed	P3	Eli Lilly and Company
A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus NCT05048719	Completed	P2	Eli Lilly and Company
A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus NCT01584232	Completed	P3	Eli Lilly and Company
A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy NCT02973100	Completed	P2	Eli Lilly and Company
A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes NCT02152371	Completed	P3	Eli Lilly and Company
Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8) NCT01769378	Completed	P3	Eli Lilly and Company
A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes NCT04591626	Completed	P3	Eli Lilly and Company
A Study of LY3437943 in Participants With Type 2 Diabetes NCT04867785	Completed	P2	Eli Lilly and Company
A Study of HS-20094 in Patients With T2DM NCT06901648	Completed	P2	Jiangsu Hansoh Pharmaceutical Co., Ltd.
A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus NCT00630825	Completed	P2	Eli Lilly and Company
A Study of IBI362 in Chinese Patients With Type 2 Diabetes NCT04965506	Completed	P2	Innovent Biologics (Suzhou) Co. Ltd.
A Study of TG103 Injection in Type 2 Diabetes Subjects NCT05348122	Unknown	P2	CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus NCT06148649	Completed	P2	Dongguan HEC Biopharmaceutical R&D Co., Ltd.
A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin NCT07109700	Recruiting	P2	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India NCT05659537	Completed	P4	Eli Lilly and Company
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes NCT07668336	Recruiting	P3	Eli Lilly and Company
Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes NCT00791479	Completed	P2	Eli Lilly and Company
A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes NCT02750410	Completed	P4	Eli Lilly and Company
A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes NCT02963766	Completed	P3	Eli Lilly and Company
A Study of LY2189265 in Japanese Patients With Type 2 Diabetes NCT01001104	Completed	P2	Eli Lilly and Company
Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D NCT05140694	Unknown	P4	Seoul National University Bundang Hospital
The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity. NCT05005741	Unknown	P4	Second Xiangya Hospital of Central South University
Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST) NCT03648554	Unknown	P4	Central Hospital, Nancy, France
A Phase 2, 12-Week, Double-Blind, Efficacy and Safety of GX-G6 in Patients With Uncontrolled Type 2 Diabetes Mellitus NCT03962010	Unknown	P2	Genexine, Inc.
Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus NCT07677891	Not yet recruiting	P2	ProGen. Co., Ltd.
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) NCT06739122	Recruiting	P3	Eli Lilly and Company
Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes NCT04893148	Unknown	P4	Chungbuk National University Hospital
Effect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 Diabetes NCT03444142	Unknown	P4	University of Guadalajara
A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes NCT03315780	Completed	P4	Eli Lilly and Company

See the full record for dulaglutide, or every molecule being studied in type 2 diabetes. These are registered trials, nothing more. Most drugs tested in a new condition never get approved for it, and plenty of these will report nothing useful.